Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Chronic Obstructive Pulmonary Disease | Unmet Need | Severe to Very Severe | US/EU | 2024
The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, and, most recently, LABA/LAMA/ICSs…
Chronic Obstructive Pulmonary Disease | Treatment Algorithms: Claims Data Analysis | US | 2024
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have been gaining traction in the chronic obstructive pulmonary disease (COPD) market,…
Chronic Obstructive Pulmonary Disease | Disease Landscape & Forecast | G7 | 2023
The chronic obstructive pulmonary disease (COPD) therapy market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics…
Chronic Obstructive Pulmonary Disease | Treatment Algorithms: Claims Data Analysis | US | 2023
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have been gaining traction in the chronic obstructive pulmonary disease (COPD) therapy…
Chronic Obstructive Pulmonary Disease | Disease Landscape & Forecast | G7 | 2022
The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics will…
Chronic obstructive pulmonary disease | Treatment Algorithms: Claims Data Analysis | US | 2022
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the chronic obstructive pulmonary disease (COPD) market,…
